Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal-Reference-Cited by-同舟云学术

Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

Published:2022-02-25 Issue:2 Volume:19 Page:476-490
ISSN:1933-7213
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Rollot Fabien^ORCID,Couturier Justine,Casey Romain,Wiertlewski Sandrine,Debouverie Marc,Pelletier Jean,De Sèze Jérôme,Labauge Pierre,Ruet Aurélie,Thouvenot Eric,Ciron Jonathan,Berger Eric,Gout Olivier,Clavelou Pierre,Stankoff Bruno,Casez Olivier,Bourre Bertrand,Zephir Hélène,Moreau Thibault,Lebrun-Frenay Christine,Maillart Elisabeth,Edan Gilles,Neau Jean-Philippe,Montcuquet Alexis,Cabre Philippe,Camdessanché Jean-Philippe,Defer Gilles,Nasr Haifa Ben,Maurousset Aude,Hankiewicz Karolina,Pottier Corinne,Leray Emmanuelle,Vukusic Sandra,Laplaud David-Axel

Funder

Agence Nationale de la Recherche

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13311-022-01202-1.pdf

Reference34 articles.

1. Kappos L, Radue E-W, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387‑401.

2. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402‑15.

3. Kappos L, O’Connor P, Radue E-W, Polman C, Hohlfeld R, Selmaj K, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84(15):1582‑91.